Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 17/20 | 0.45 |
| ▸ | AKT2 | P31751 | 17/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10141161 | 1.00 | KMT2A (0.55) | KMT2AAKT1AKT2PTGS2 | |
| SCHEMBL513070 | 1.00 | KMT2A (0.55) | KMT2AAKT1AKT2PTGS2 | |
| SCHEMBL513272 | 0.88 | AKT1 (0.47) | KMT2AAKT1AKT2 | |
| SCHEMBL10141155 | 0.88 | AKT1 (0.47) | KMT2AAKT1AKT2 | |
| SCHEMBL513271 | 0.88 | AKT1 (0.47) | KMT2AAKT1AKT2 | |
| SCHEMBL513563 | 0.88 | AR (0.45) | KMT2AAKT1AKT2PTGS2 | |
| SCHEMBL513564 | 0.88 | AR (0.45) | KMT2AAKT1AKT2PTGS2 | |
| SCHEMBL10141153 | 0.88 | AR (0.45) | KMT2AAKT1AKT2PTGS2 | |
| SCHEMBL514276 | 0.88 | AKT1 (0.46) | KMT2AAKT1AKT2 | |
| SCHEMBL10141157 | 0.88 | AKT1 (0.46) | KMT2AAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | LIANG PENG (CN) | 2013-04-25 | — | — | US | claimed |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | LIANG PENG (CN) | 2013-04-25 | — | — | US | disclosed |
| EP-2579872-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | KMT2A 2913/4885AKT1 172/4885AKT2 121/4885 |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, PIK3CD, AKT2 | KMT2A 1650/4885AKT1 8/4885AKT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.